Mark W. Frampton, M.D.

Mark W. Frampton, M.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 692
Rochester, NY 14642

Office: (585) 275-4161
Fax: (585) 273-1171
Administrative: (585) 275-4861

Professional Bio

Dr. Mark Frampton is Professor of Medicine and Environmental Medicine in the Pulmonary and Critical Care Division at the University of Rochester School of Medicine. He received his MD from New York University School of Medicine and then trained in Internal Medicine at Buffalo General Hospital. After nine years of private practice in Williamson, New York, he completed Pulmonary and Critical Care training at the University of Rochester, and then joined the faculty. His primary research interest is the health effects of air pollution, and he directs an NIH-funded training program in pulmonary research.

Dr. Frampton directs the Pulmonary Function Laboratory at Strong Memorial Hospital. He has an active outpatient pulmonary clinic, seeing a broad spectrum of patients with pulmonary diseases, and also attends and teaches on the Pulmonary Consultation Service at Strong Memorial Hospital. He has a special interest in tuberculosis, having directed the Wayne County Tuberculosis Clinic for more than 30 years, and has been caring for patients with tuberculosis infection and disease at the Monroe County Health Department for more than 20 years.

Research Bio

Each day the average person breathes about 15,000 liters, or approximately 35 pounds, of air. Gaseous and particulate contaminants in that air gain access to the body with each breath, and may have both short and long-term effects on human health. Our ongoing studies examine the effects of particle exposure on lung function, airway inflammation, and cardiovascular function. Utilizing both environmental chamber and mouthpiece exposure systems, subjects are exposed to environmentally relevant concentrations of pollutants, with or without exercise. Respiratory and systemic effects are determined using measures of lung function, examination for markers of inflammation in exhaled air, characterization of blood leukocyte and platelet responses using 3-color flow cytometry, and detailed cardiovascular monitoring.

Ultrafine particles (UFP, <100 nm diameter) may be particularly important with regard to cardiovascular effects because of their potential for evading clearance mechanisms and entering the lung interstitium and vascular space. We have demonstrated in healthy nonsmokers that inhalation of low concentrations of UFP causes changes in leukocyte expression of adhesion molecules, and reductions in the pulmonary diffusing capacity, that are consistent with altered endothelial function. The elderly and people with underlying vascular disease, such as diabetics, may be more susceptible to vascular effects of particle exposure because of impaired endothelial function and increased risk for atherosclerosis. Our studies explore the hypothesis that inhalation of ultrafine particles alters endothelial function in healthy and susceptible people. Endothelial dysfunction is critically linked to the pathogenesis of atherosclerotic vascular disease. Data from these human clinical studies of exposure to air pollutants help to elucidate the mechanisms responsible for pollutant health effects, and assist in establishing rational air quality standards.

Awards & Honors (Local)

Fellow, American College of Physicians 1974 - Present

Recent Journal Articles

Showing the 5 most recent journal articles. 107 available »

2016 Dec 1
Ettensohn DB, Frampton MW, Nichols JE, Roberts NJ. "Human Alveolar Macrophages May Not Be Susceptible to Direct Infection by a Human Influenza Virus." The Journal of infectious diseases. 2016 Dec 1; 214(11):1658-1665. Epub 2016 Sep 06.
2016 Aug
Wang M, Utell MJ, Schneider A, Zareba W, Frampton MW, Oakes D, Hopke PK, Wiltshire J, Kane C, Peters A, Breitner S, Chalupa D, Rich DQ. "Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation?" Environmental research. 2016 Aug; 149:15-22. Epub 2016 May 10.
Becerra AZ, Georas S, Brenna JT, Hopke PK, Kane C, Chalupa D, Frampton MW, Block R, Rich DQ. "Increases in ambient particulate matter air pollution, acute changes in platelet function, and effect modification by aspirin and omega-3 fatty acids: A panel study." Journal of toxicology and environmental health. Part A. 2016 79(6):287-98. Epub 2016 Mar 30.
2015 Feb
Frampton MW, Pietropaoli A, Dentler M, Chalupa D, Little EL, Stewart J, Frasier L, Oakes D, Wiltshire J, Vora R, Utell MJ. "Cardiovascular effects of ozone in healthy subjects with and without deletion of glutathione-S-transferase M1." Inhalation toxicology. 2015 Feb; 27(2):113-9.
2014 Jul 16
Vora R, Zareba W, Utell MJ, Pietropaoli AP, Chalupa D, Little EL, Oakes D, Bausch J, Wiltshire J, Frampton MW. "Inhalation of ultrafine carbon particles alters heart rate and heart rate variability in people with type 2 diabetes." Particle and fibre toxicology. 2014 Jul 16; 11:31. Epub 2014 Jul 16.

Current Appointments

Professor Emeritus - Department of Medicine, Pulmonary Diseases and Critical Care (SMD) - Primary


Pulmonary Disease - American Board of Internal Medicine
Critical Care Medicine - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine


MD | Medicine | New York Univ Sch Medicine1973
Mathematics, Microbiology | California State University, Long BeachAttended 1965 - 1969

Post-Doctoral Training & Residency

Fellowship in Pulmonary & Critical Care at University of Rochester Medical Center07/01/1985 - 06/30/1988
Residency in Internal Medicine at Buffalo General Hospital07/01/1974 - 06/30/1976
Internship in Internal Medicine at Buffalo General Hospital07/01/1973 - 06/30/1974